Skip to main content
SpringerLink
Log in

Comparison Between a Single Dose of Goserelin (Depot) and Multiple Daily Doses of Leuprolide Acetate for Pituitary Suppression in IVF Treatment: A Clinical Endocrinological Study of the Ovarian Response

  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purpose : Compare the efficacy and safety of two different GnRHa, used for pituitary suppression in IVF cycles.

Methods : A total of 292 patients using depot goserelin (Group 1) and 167 using daily leuprolide acetate (Group 2) were compared. Days required to achieve pituitary function suppression, duration of ovarian stimulation, total dose of HMG, number of aspirated follicles, number of oocytes retrieved, and presence of functional ovarian cyst were analyzed.

Results : The time taken to achieve downregulation was similar. The mean number of ampoules used for superovulation was higher in Group 1; however, this difference was observed only for patients >40 years old that started GnRHa in the follicular phase. There was no difference between the two groups in the duration of superovulation, in the number of follicles aspirated, and the number of oocytes retrieved. In the group of patients with >40 years the incidence of ovarian cysts was higher in Group 2.

Conclusions : Both routes of GnRHa have similar effects for pituitary suppression and ovulation induction in assisted reproductive technology. Therefore the long-acting GnRHa is an excellent option, as only a single subcutaneous dose is necessary, decreasing the risk of the patient to forget its use and, most important, it does not interfere in the patient's quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Fleming R, Adam AH, Barlow DH, Black WP, MacNaughton MC, Coutts JR: A new systematic treatment for infertile women with abnormal hormone profiles. Br J Obstet Gynaecol 1982;89:80–83

    Google Scholar 

  2. Neveu S, Hedon B, Bringer J, Chinchole JM, Arnal F, Humeau J, Cristol P, Viala JL: Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization. Fertil Steril 1987;47:639–643

    Google Scholar 

  3. Dor J, Shulman A, Pariente A, Levran D, Bider D, Menashe Y, Mashiach S: The effect of gonadotropin-releasing hormone agonist in the ovarian response and in vitro fertilization results in polycistic ovarian syndrome: A prospective study. Fertil Steril 1992;57:366–371

    Google Scholar 

  4. Smitz J, Van Den Abbeel E, Camus M, Devroy P, Touaye H, Van Steirtegheim AC: The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in vitro fertilization outcome in normo-ovulatory women. Hum Reprod 1992;7:1098–1102

    Google Scholar 

  5. Tummon IS, Daniel SA, Kaplan BR, Nisker JA, Yuzpe AA: Randomized, prospective comparison of luteal leuprolide acetate and gonadotropins versus clomiphene citrate and gonadotropin in 408 first cycles of in vitro fertilization. Fertil Steril 1992;58:563–568

    Google Scholar 

  6. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van deKoppel P, Collins JA: The routine use of gonadotrophin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: A meta-analysis of randomized controlled trials. Fertil Steril 1992;58:888–896

    Google Scholar 

  7. Dimitry ES, Bates SA, Oskarsson T, Margara RA, Winston RML: Programming in vitro fertilization for a 5-or 3-day week. Fertil Steril 1991;55:934–938

    Google Scholar 

  8. Polan ML, Daniele A, Russel JB, DeCherney AH: Ovulation induction with human menopausal gonadotropin compared to urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosa-luteal cell function. J Clin Endocrinol Metab 1986;63:1284–1291

    Google Scholar 

  9. Awadalla SG, Friedman CL, Chin NW, Dods W, Park JM, Kim MH: Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins. Fertil Steril 1987;48:811–815

    Google Scholar 

  10. Porter RN, Smith W, Craft IL, Abduwahid NA, Jacobs HS: Induction of ovulation for in vitro fertilisation using buserelin and gonadotrophins. (Letter.) Lancet 1984;ii:1284–1285

    Google Scholar 

  11. Frydman R, Belaisch AJ, Parneix I, Forman R, Hazout A, Rainhorn JD, Fries N, Testart J: Comparison between flare up and down regulation effects of luteinizing hormone-releasing hormone agonist in an in vitro fertilization program. Fertil Steril 1988;50:471–475

    Google Scholar 

  12. Abdalla HI, Ahuja KK, Leonard T, Morris NN, Honour JW, Jacobs HS: Comparative trial of luteinizing hormonereleasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program. Fertil Steril 1990;53:473–478

    Google Scholar 

  13. Tan SL, Kingsland C, Campbell S, Mills C, Bradfield J, Alexander N, Yovich J, Jacobs HS: The long protocol of administration of gonadotrophin-releasing hormone agonist is superior to the short protocol for ovarian stimulation for in vitro fertilization. Fertil Steril 1992;57:810–814

    Google Scholar 

  14. Filicori M, Flamigni C, Cognigni G, Falbo A, Arnone R, Capelli M, Pavani A, Mandini M, Calderoni P, Brondelli L: Different gonadotropin and leuprorelin ovulation induction regimens markedly affect follicular fluid hormone levels and folliculogenesis. Fertil Steril 1996;65:387–393

    Google Scholar 

  15. Tapanainen J, Hovatta O, Juntunen K, Martikainen H, Ratsula K, Tulppala M, Tuomivaara L: Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: A randomized comparative study. Hum Reprod 1993;8:2052–2055

    Google Scholar 

  16. Oyesanya OA, Teo SK, Quah E, Abdurazak N, Lee FY, Cheng WC: Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: A comparison between a single dose of Zoladex depot and multiple daily doses of suprefact. Hum Reprod 1995;10:1042–1044

    Google Scholar 

  17. Geber S, Sampaio M: Blastomere development after embryo biopsy: A new model to predict embryo development and to select for transfer. Hum Reprod 1999;14:782–786

    Google Scholar 

  18. Filicori M, Flamigni C, Cognigni G, Dellai P, Arnone R, Falbo A, Capelli M: Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 1993;77:130–133

    Google Scholar 

  19. Dhont M, Onghena A, Coetsier T, De Sutter P: Prospective randomized study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction. Hum Reprod 1995;10:791–796

    Google Scholar 

  20. Lockwood GM, Pinkerton SM, Barlow DH: A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.Hum Reprod 1995;10:293–298

    Google Scholar 

  21. Porcu E, Filicori M, Dal PL, Fabbri R, Seracchioli R, Colombi C, Flamigni C: Comparison between depot leuprorelin and daily buserelin in IVF.J Assist Reprod Genet 1995;12:15–19

    Google Scholar 

  22. Ron El R, Herman A, Golan A, Van der Venet H, Caspi E, Dietrich K: The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist. Fertil Steril 1990;54:233–237

    Google Scholar 

  23. Alvarez C, Cremades N, Blasco N, Bernabeu R: Influence of gonadotrophin-releasing hormone agonist total dose in the ovarian stimulation in the long down-regulation protocol for in-vitro fertilization. Hum Reprod 1997;12:2366–2369

    Google Scholar 

  24. Sampaio M, Serra V, Miro F, Calatayud C, Castellvi RM, Pellicer A: Development of ovarian cysts during gonadotrophin-releasing hormone agonists (GnRHa) administration. Hum Reprod 1991;6:194–197

    Google Scholar 

  25. Tarlatzis BC, Bili H, Bontis J, Lagos S, Vatev I, Mantalenakis S: Follicle cyst formation after administration of different gonadotrophin-releasing hormone analogues for assisted reproduction. Hum Reprod 1994;9:1983–1986

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro de Medicina Reprodutiva, ORIGEN, Av Contorno 7747, Belo Horizonte, Minas Gerais, CEP 30110120, Brazil

    Selmo Geber, Liana Sales & Marcos A. C. Sampaio

  2. Department of Obstetrics and Gynaecology, Federal University of Minas Gerais, Minas Gerais, Brazil

    Selmo Geber

Authors
  1. Selmo Geber
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liana Sales
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marcos A. C. Sampaio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Selmo Geber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Geber, S., Sales, L. & Sampaio, M.A.C. Comparison Between a Single Dose of Goserelin (Depot) and Multiple Daily Doses of Leuprolide Acetate for Pituitary Suppression in IVF Treatment: A Clinical Endocrinological Study of the Ovarian Response. J Assist Reprod Genet 19, 313–318 (2002). https://doi.org/10.1023/A:1016054424966

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016054424966

Search

Navigation